---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-081006"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2022-07-20T23:59:59+00:00"
generated_at: "2026-06-24T11:33:49.470250+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Abbott Q2 EPS $1.14 GAAP, $1.43 adj; raises FY adj EPS view to $4.90+

## Summary
- Q2 sales $11.3B (+10.1% reported, +14.3% organic); GAAP EPS $1.14, adjusted EPS $1.43 (+22.2%).
- COVID-19 testing sales $2.3B in Q2; full-year COVID testing revenue projected at $6.1B.
- Raised FY 2022 GAAP EPS guidance to at least $3.50, adjusted EPS to at least $4.90.
- Nutrition sales down 7.4% reported due to infant formula recall; Adult Nutrition organic growth +5.2%.
- Medical Devices organic growth +7.5% driven by Diabetes Care FreeStyle Libre (+25.6% organic).

## SEC filing metadata
- accession: 0001104659-22-081006
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2022-07-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000110465922081006/0001104659-22-081006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000110465922081006/tm2221376d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-081006
- JSON: https://secwatch.observer/filing/0001104659-22-081006.json
- Plain text: https://secwatch.observer/filing/0001104659-22-081006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.